The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What non-cellular immunotherapies are in development for multiple myeloma?

Dec 13, 2019

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Adam D. Cohen, University of Pennsylvania, Philadelphia, US, answers the question: What non-cellular immunotherapies are in development for multiple myeloma?

Dr Cohen discusses the two main categories of non-cellular immunotherapies; antibody-drug conjugates and bispecific antibodies, and provides a summary of the latest data of these agents from clinical trials. Dr Cohen concludes that whilst trials investigating both classes of agents are in early stages, they may provide new therapeutic options to patients with relapsed/refractory multiple myeloma.

What non-cellular immunotherapies are in development for multiple myeloma?